Future directions for immune modulation in neurodegenerative disorders: Focus on Parkinson's disease

Journal of Neural Transmission

Volumn 117, Issue 8, 2010, Pages 1019-1025

  Maguire Zeiss, Kathleen A ^a   Federoff, Howard J ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Neuroinflammation; Nurr1; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CYTOKINE; NUCLEAR RECEPTOR RELATED FACTOR 1; VASOACTIVE INTESTINAL POLYPEPTIDE;

CELL FUNCTION; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; ENCEPHALITIS; HUMAN; IMMUNOMODULATION; MESENCEPHALON; MICROGLIA; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; REVIEW;

ANIMALS; DISEASE PROGRESSION; DOPAMINE; ENCEPHALITIS; HUMANS; INFLAMMATION MEDIATORS; MODELS, BIOLOGICAL; PARKINSON DISEASE;

EID: 77956977811     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-010-0431-6     Document Type: Review

References (67)

1. TB Ahn SY Kim, et al. 2008 alpha-Synuclein gene duplication is present in sporadic Parkinson disease Neurology 70 1 43 49 10.1212/01.wnl.0000271080. 53272.c7 17625105 1:CAS:528:DC%2BD2sXhsVGgtbbK
2. KN Alavian C Scholz, et al. 2008 Transcriptional regulation of mesencephalic dopaminergic neurons: the full circle of life and death Mov Disord 23 3 319 328 10.1002/mds.21640 18044702
3. RB Banati 2002 Visualising microglial activation in vivo Glia 40 2 206 217 10.1002/glia.10144 12379908
4. AL Bartels KL Leenders 2007 Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET Mov Disord 22 13 1852 1856 10.1002/mds.21552 17592621
5. AL Bartels AT Willemsen, et al. 2010 [11C]-PK11195 PET: quantification of neuroinflammation and a monitor of anti-inflammatory treatment in Parkinson's disease? Parkinsonism Relat Disord 16 1 57 59 10.1016/j.parkreldis.2009.05.005 19487152 1:STN:280:DC%2BC3c%2FpvFGgtg%3D%3D
6. SJ Bensinger P Tontonoz 2009 A Nurr1 pathway for neuroprotection Cell 137 1 26 28 10.1016/j.cell.2009.03.024 19345183 1:CAS:528:DC%2BD1MXls1Srsr8%3D
7. H Braak K Del Tredici 2008 Invited article: nervous system pathology in sporadic Parkinson disease Neurology 70 20 1916 1925 10.1212/01.wnl.0000312279. 49272.9f 18474848
8. DE Brenneman G Glazner, et al. 1998 VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide Ann N Y Acad Sci 865 207 212 10.1111/j.1749-6632.1998. tb11180.x 9928014 1:CAS:528:DyaK1MXmvFWlsA%3D%3D
9. DJ Brooks 2007 Assessment of Parkinson's disease with imaging Parkinsonism Relat Disord 13 Suppl 3 S268 S275 10.1016/S1353-8020(08)70015-4 18267249
10. M Bucciantini E Giannoni, et al. 2002 Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases Nature 416 6880 507 511 10.1038/416507a 11932737 1:CAS:528:DC%2BD38XivVOgtbg%3D
11. MF Chesselet 2008 In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease? Exp Neurol 209 1 22 27 10.1016/j.expneurol. 2007.08.006 17949715 1:CAS:528:DC%2BD1cXivFeitw%3D%3D
12. KA Conway SJ Lee, et al. 2000 Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy Proc Natl Acad Sci USA 97 2 571 576 10.1073/pnas.97.2.571 10639120 1:CAS:528:DC%2BD3cXot1ajtw%3D%3D
13. A Dejda P Sokolowska, et al. 2005 Neuroprotective potential of three neuropeptides PACAP, VIP and PHI Pharmacol Rep 57 3 307 320 15985713 1:CAS:528:DC%2BD2MXhtVClurnK
14. M Delgado D Ganea 2003 Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation FASEB J 17 8 944 946 12626429 1:CAS:528:DC%2BD3sXjsFaksLc%3D
15. M Delgado D Ganea 2003 Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma FASEB J 17 13 1922 1924 12923064 1:CAS:528:DC%2BD3sXot1Kit74%3D
16. M Delgado GM Jonakait, et al. 2002 Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia Glia 39 2 148 161 10.1002/glia.10098 12112366
17. M Delgado J Leceta, et al. 2003 Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia J Leukoc Biol 73 1 155 164 10.1189/jlb.0702372 12525573 1:CAS:528:DC%2BD3sXnvVyhug%3D%3D
18. ER Dorsey R Constantinescu, et al. 2007 Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 Neurology 68 5 384 386 10.1212/01.wnl.0000247740.47667.03 17082464 1:STN:280: DC%2BD2s%2FlsFOmug%3D%3D
19. JS Dubow 2007 Autonomic dysfunction in Parkinson's disease Dis Mon 53 5 265 274 10.1016/j.disamonth.2007.02.004 17656188
20. JL Eberling WJ Jagust, et al. 2008 Results from a phase I safety trial of hAADC gene therapy for Parkinson disease Neurology 70 21 1980 1983 10.1212/01.wnl.0000312381.29287.ff 18401019 1:CAS:528:DC%2BD1cXlvVCmtro%3D
21. OM El-Agnaf S Nagala, et al. 2001 Non-fibrillar oligomeric species of the amyloid ABri peptide, implicated in familial British dementia, are more potent at inducing apoptotic cell death than protofibrils or mature fibrils J Mol Biol 310 1 157 168 10.1006/jmbi.2001.4743 11419943 1:CAS:528:DC%2BD3MXksFSrsrk%3D
22. OM El-Agnaf DM Walsh, et al. 2003 Soluble oligomers for the diagnosis of neurodegenerative diseases Lancet Neurol 2 8 461 462 10.1016/S1474-4422(03) 00481-2 12878433
23. HJ Federoff 2009 Nur(R1)turing a notion on the etiopathogenesis of Parkinson's disease Neurotox Res 16 3 261 270 10.1007/s12640-009-9056-7 19526279 1:CAS:528:DC%2BD1MXhtFOkt7bP
24. A Gerhard N Pavese, et al. 2006 In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease Neurobiol Dis 21 2 404 412 10.1016/j.nbd.2005.08.002 16182554 1:CAS:528:DC%2BD28XmsVGmsg%3D%3D
25. MB Graeber WJ Streit 2010 Microglia: biology and pathology Acta Neuropathol 119 1 89 105 10.1007/s00401-009-0622-0 20012873
26. LT Grinberg U Rueb, et al. 2010 Brainstem pathology and non-motor symptoms in PD J Neurol Sci 289 1-2 81 88 10.1016/j.jns.2009.08.021 19758601
27. K Imamura N Hishikawa, et al. 2003 Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains Acta Neuropathol 106 6 518 526 10.1007/s00401-003- 0766-2 14513261 1:CAS:528:DC%2BD3sXos1Clsrs%3D
28. J Jankovic S Chen, et al. 2005 The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease Prog Neurobiol 77 1-2 128 138 10.1016/j.pneurobio.2005.09.001 16243425 1:CAS:528:DC%2BD2MXht1GhtbvP
29. MG Kaplitt A Feigin, et al. 2007 Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial Lancet 369 9579 2097 2105 10.1016/S0140-6736(07)60982- 9 17586305 1:CAS:528:DC%2BD2sXmvVKqtb4%3D
30. H Kaufmann K Nahm, et al. 2004 Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies Neurology 63 6 1093 1095 15452307
31. TK Khoo DJ Burn 2009 Non-motor symptoms may herald Parkinson's disease Practitioner 253 1721 19 24 19873855
32. K Krogh K Ostergaard, et al. 2008 Clinical aspects of bowel symptoms in Parkinson's disease Acta Neurol Scand 117 1 60 64 18095955 1:STN:280: DC%2BD2sjlvVSguw%3D%3D
33. R Kruger W Kuhn, et al. 1998 Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease Nat Genet 18 2 106 108 10.1038/ng0298-106 9462735 1:CAS:528:DyaK1cXosFCntA%3D%3D
34. N Lapointe M St-Hilaire, et al. 2004 Rotenone induces non-specific central nervous system and systemic toxicity FASEB J 18 6 717 719 14766796 1:CAS:528:DC%2BD2cXjtVyrs7o%3D
35. W Le OM Conneely, et al. 1999 Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury J Neurochem 73 5 2218 2221 10537083 1:CAS:528:DyaK1MXntVWitLw%3D
36. WD Le P Xu, et al. 2003 Mutations in NR4A2 associated with familial Parkinson disease Nat Genet 33 1 85 89 10.1038/ng1066 12496759 1:CAS:528:DC%2BD38XpvVeqs7Y%3D
37. W Le T Pan, et al. 2008 Decreased NURR1 gene expression in patients with Parkinson's disease J Neurol Sci 273 1-2 29 33 10.1016/j.jns.2008.06.007 18684475 1:CAS:528:DC%2BD1cXhtVKju7%2FN
38. HJ Lee JE Suk, et al. 2010 Direct transfer of alpha-synuclein from neuron to astroglia causes inflammatory responses in synucleinopathies J Biol Chem 285 12 9262 9272 10.1074/jbc.M109.081125 20071342 1:CAS:528:DC%2BC3cXjtFShtLk%3D
39. Y Luo LA Henricksen, et al. 2007 VIP is a transcriptional target of Nurr1 in dopaminergic cells Exp Neurol 203 1 221 232 10.1016/j.expneurol.2006.08.005 16999955 1:CAS:528:DC%2BD28Xht1Krt73O
40. Y Luo F Xing, et al. 2008 Identification of a novel nurr1-interacting protein J Neurosci 28 37 9277 9286 10.1523/JNEUROSCI.3021-08.2008 18784308 1:CAS:528:DC%2BD1cXht1Sns7nO
41. KA Maguire-Zeiss 2008 alpha-Synuclein: a therapeutic target for Parkinson's disease? Pharmacol Res 58 271 280 10.1016/j.phrs.2008.09.006 18840530 1:CAS:528:DC%2BD1cXhsVChurfP
42. KA Maguire-Zeiss HJ Federoff 2009 Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases J Neuroimmune Pharmacol 4 3 298 308 10.1007/s11481-008-9133-3 18931916
43. Maguire-Zeiss KA, Su X et al (2008) Microglial activation in a mouse model of alpha-synuclein overexpression. Elsevier, San Diego
44. WJ Marks Jr JL Ostrem, et al. 2008 Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial Lancet Neurol 7 5 400 408 10.1016/S1474-4422(08)70065-6 18387850
45. PL McGeer S Itagaki, et al. 1988 Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains Neurology 38 8 1285 1291 3399080 1:STN:280:DyaL1c3ovVKkuw%3D%3D
46. D Offen Y Sherki, et al. 2000 Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease Brain Res 854 1-2 257 262 10.1016/S0006-8993(99)02375-6 10784133 1:CAS:528:DC%2BD3cXhtlyitL0%3D
47. Y Ouchi E Yoshikawa, et al. 2005 Microglial activation and dopamine terminal loss in early Parkinson's disease Ann Neurol 57 2 168 175 10.1002/ana.20338 15668962 1:CAS:528:DC%2BD2MXhs1Cisb8%3D
48. Y Ouchi S Yagi, et al. 2009 Neuroinflammation in the living brain of Parkinson's disease Parkinsonism Relat Disord 15 Suppl 3 S200 S204 10.1016/S1353-8020(09)70814-4 20082990
49. T Perlmann A Wallen-Mackenzie 2004 Nurr1, an orphan nuclear receptor with essential functions in developing dopamine cells Cell Tissue Res 318 1 45 52 10.1007/s00441-004-0974-7 15340833 1:CAS:528:DC%2BD2cXos1aqsbs%3D
50. W Poewe 2007 Dysautonomia and cognitive dysfunction in Parkinson's disease Mov Disord 22 Suppl 17 S374 S378 10.1002/mds.21681 18175399
51. MH Polymeropoulos 2000 Genetics of Parkinson's disease Ann N Y Acad Sci 920 28 32 10.1111/j.1749-6632.2000.tb06901.x 11193165 1:CAS:528: DC%2BD3MXotlWrug%3D%3D
52. MH Polymeropoulos JJ Higgins, et al. 1996 Mapping of a gene for Parkinson's disease to chromosome 4q21-q23 Science 274 5290 1197 1199 10.1126/science.274.5290.1197 8895469 1:CAS:528:DyaK28XmvVyit74%3D
53. K Saijo B Winner, et al. 2009 A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death Cell 137 1 47 59 10.1016/j.cell.2009.01.038 19345186 1:CAS:528:DC%2BD1MXls1Srsro%3D
54. W Satake Y Nakabayashi, et al. 2009 Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease Nat Genet 41 12 1303 1307 10.1038/ng.485 19915576 1:CAS:528: DC%2BD1MXhsVWlsb7O
55. J Simon-Sanchez C Schulte, et al. 2009 Genome-wide association study reveals genetic risk underlying Parkinson's disease Nat Genet 41 12 1308 1312 10.1038/ng.487 19915575 1:CAS:528:DC%2BD1MXhsVWlsbrP
56. AB Singleton M Farrer, et al. 2003 alpha-Synuclein locus triplication causes Parkinson's disease Science 302 5646 841 10.1126/science.1090278 14593171 1:CAS:528:DC%2BD3sXoslehsbc%3D
57. A Singleton K Gwinn-Hardy, et al. 2004 Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication Brain 127 Pt 4 768 772 10.1093/brain/awh081 14736756
58. MG Spillantini ML Schmidt, et al. 1997 Alpha-synuclein in Lewy bodies Nature 388 6645 839 840 10.1038/42166 9278044 1:CAS:528:DyaK2sXlslWru7o%3D
59. MG Spillantini RA Crowther, et al. 1998 alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies Proc Natl Acad Sci USA 95 11 6469 6473 10.1073/pnas.95.11.6469 9600990 1:CAS:528:DyaK1cXjtlKgtLo%3D
60. X Su KA Maguire-Zeiss, et al. 2008 Synuclein activates microglia in a model of Parkinson's disease Neurobiol Aging 29 11 1690 1701 10.1016/j.neurobiolaging.2007.04.006 17537546 1:CAS:528:DC%2BD1cXhtFCksLzE
61. X Su HJ Federoff, et al. 2009 Mutant alpha-synuclein overexpression mediates early proinflammatory activity Neurotox Res 16 3 238 254 10.1007/s12640-009-9053-x 19526281 1:CAS:528:DC%2BD1MXhtFOkt7nF
62. MJ Thiruchelvam JM Powers, et al. 2004 Risk factors for dopaminergic neuron loss in human alpha-synuclein transgenic mice Eur J Neurosci 19 4 845 854 10.1111/j.0953-816X.2004.03139.x 15009131 1:STN:280:DC%2BD2c7hvFensA%3D%3D
63. E Tolosa Y Compta, et al. 2007 The premotor phase of Parkinson's disease Parkinsonism Relat Disord 13 Suppl S2 S7 10.1016/j.parkreldis.2007.06.007 17681839
64. Z Wang G Benoit, et al. 2003 Structure and function of Nurr1 identifies a class of ligand-independent nuclear receptors Nature 423 6939 555 560 10.1038/nature01645 12774125 1:CAS:528:DC%2BD3sXktVygtb4%3D
65. RH Zetterstrom L Solomin, et al. 1997 Dopamine neuron agenesis in Nurr1-deficient mice Science 276 5310 248 250 10.1126/science.276.5310.248 9092472 1:STN:280:DyaK2s3kvVKgtw%3D%3D
66. W Zhang T Wang, et al. 2005 Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease FASEB J 19 6 533 542 10.1096/fj.04-2751com 15791003 1:CAS:528:DC%2BD2MXjtFaqsrc%3D
67. K Zheng B Heydari, et al. 2003 A common NURR1 polymorphism associated with Parkinson disease and diffuse Lewy body disease Arch Neurol 60 5 722 725 10.1001/archneur.60.5.722 12756136